Abstract: The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed to Staphylococci.
Type:
Grant
Filed:
September 9, 2013
Date of Patent:
April 28, 2015
Assignee:
Hyglos Invest GmbH
Inventors:
Michael Forchheim, Holger Grallert, Anja Philipp, Manfred Biebl
Abstract: The invention provides a variety of molecular tools for use in live-cell tracking of activities of biomolecules and in high-throughput drug screening.
Type:
Grant
Filed:
August 20, 2008
Date of Patent:
April 28, 2015
Assignee:
The Johns Hopkins University
Inventors:
Jin Zhang, Robert Howard Newman, Xinxin Gao, Michael David Allen, Matthew David Fosbrink
Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.
Type:
Application
Filed:
December 16, 2014
Publication date:
April 23, 2015
Inventors:
Ashutosh Chilkoti, Felipe Garcia Quiroz, Miriam Amiram
Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.
Type:
Application
Filed:
September 4, 2012
Publication date:
April 23, 2015
Applicant:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.
Abstract: The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same.
Type:
Application
Filed:
October 17, 2014
Publication date:
April 23, 2015
Applicant:
SANOFI VACCINE TECHNOLOGIES, S.A.S.
Inventors:
Anne-Cecile V. BAYNE, James Casey LIPPMEIER, Kirk Emil APT, Ross Eric ZIRKLE
Abstract: The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.
Type:
Application
Filed:
May 3, 2013
Publication date:
April 23, 2015
Inventors:
Alessandro Sette, Bjoern Peters, Jason Greenbaum
Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
Type:
Application
Filed:
December 2, 2014
Publication date:
April 23, 2015
Inventors:
Oliver HILL, Christian Gieffers, Meinolf Thiemann
Abstract: The present invention includes compounds that are useful for treating or preventing a HIV-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an HIV-1 virus. The presented invention further includes a method of causing virolysis of a virus using the compounds described therein. The presented invention further includes a method of treating or preventing an HIV-1 infection in a mammal in need thereof using the compositions described therein.
Type:
Application
Filed:
October 22, 2014
Publication date:
April 23, 2015
Inventors:
Cameron Frank Abrams, Irwin M. Chaiken, Mark R. Contarino, Bibek Parajuli, Adel Ahmed Rashad Ahmed
Abstract: The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.
Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
Type:
Application
Filed:
September 14, 2012
Publication date:
April 23, 2015
Inventors:
Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.
Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
Type:
Application
Filed:
August 8, 2012
Publication date:
April 23, 2015
Applicant:
HOWARD hUGHES MEDICAL INSTITUTE
Inventors:
Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
Abstract: The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.
Type:
Grant
Filed:
April 22, 2010
Date of Patent:
April 21, 2015
Assignee:
Alteogen, Inc.
Inventors:
Hye-Shin Chung, Seung Bum Yoo, Sang Mee Lee
Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
Type:
Grant
Filed:
March 28, 2013
Date of Patent:
April 21, 2015
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
Type:
Grant
Filed:
December 27, 2012
Date of Patent:
April 21, 2015
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
Type:
Grant
Filed:
January 25, 2013
Date of Patent:
April 21, 2015
Assignees:
Baxter International Inc., Baxter Healthcare SA
Inventors:
Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
Abstract: The present invention relates to methods and kits for evaluating the severity of a burn injury, which are based on the detection in a clinical fluid sample of skin metabolism products, such as collagen peptides which are released upon collagen degradation or synthesis.
Abstract: The present invention is directed to recombinant microalgal cells and their use in production of heterologous hemagglutinin-neuraminidase (HN) polypeptides, as well as compositions and uses thereof.
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
Type:
Application
Filed:
October 13, 2014
Publication date:
April 16, 2015
Inventors:
Shalom Goldberg, Steven Jacobs, Tricia Lin
Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.
Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
Abstract: Systems, methods, and other embodiments are described herein for obtaining products from heterogeneous feedstocks containing toxic algae. In one embodiment, a method includes collecting a heterogeneous feedstock. The heterogeneous feedstock is then processed. The embodiment further includes calculating a toxic value for the processed heterogeneous feedstock. It is then determined whether the toxic value of the processed heterogeneous feedstock satisfies a toxic threshold. In response to determining the toxic value does satisfy the toxic threshold, a product is extracted from the heterogeneous feedstock.
Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
Type:
Application
Filed:
March 11, 2013
Publication date:
April 16, 2015
Inventors:
Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
Type:
Application
Filed:
October 21, 2014
Publication date:
April 16, 2015
Applicants:
EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
Inventors:
Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
Abstract: The present invention relates to improved and integrated methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods of the present invention include those to identify a target protein modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein. Such identification and characterisation methods are useful in the development of research tools and/or therapeutics, such protein/peptide or small molecule therapeutics. Accordingly, the present invention also relates to methods of: identification of a ligand, such as a small molecule ligand, that binds to such a target protein; and identification a compound being a candidate modulator of said phenotype of a mammalian cell.
Abstract: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.
Abstract: Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X4WX5YX6 as defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.
Type:
Application
Filed:
July 15, 2014
Publication date:
April 16, 2015
Applicant:
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Abstract: Embodiments of the invention are directed to a composition comprising a recombinant protein in soluble form wherein said recombinant protein comprises a portion of the Clostridium difficile toxin B sequence that comprises an epitope for anti-toxin B antibody. Other embodiments of the invention are directed to the generation of antibodies using peptide fragments of C. difficile toxin B.
Type:
Application
Filed:
September 13, 2012
Publication date:
April 16, 2015
Applicant:
Board of Regents of the University of Oklahoma
Inventors:
Jimmy D. Ballard, Jordi M. Melton, Latisha Heinlen, Elaine E. Hamm
Abstract: The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's disease. In addition, the invention also provides as kits for use in the diagnosis of Map infections and vaccines/immunogenic compositions.
Type:
Grant
Filed:
May 29, 2009
Date of Patent:
April 14, 2015
Assignee:
Moredun Research Institute
Inventors:
Karen Stevenson, Valerie Margaret Hughes
Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.
Type:
Grant
Filed:
May 25, 2012
Date of Patent:
April 14, 2015
Assignee:
MedImmune Limited
Inventors:
Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Type:
Grant
Filed:
September 25, 2012
Date of Patent:
April 14, 2015
Assignee:
Novartis AG
Inventors:
Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays.
Type:
Grant
Filed:
October 7, 2010
Date of Patent:
April 14, 2015
Assignee:
The Secretary of State for Health
Inventors:
Clifford Charles Shone, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
April 14, 2015
Assignee:
Universitat Zurich
Inventors:
Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate MEK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.
Type:
Grant
Filed:
October 4, 2013
Date of Patent:
April 14, 2015
Assignee:
Intrexon Corporation
Inventors:
David Bachinsky, Jonathan Carson, Amy Atzel, Thomas Reed
Abstract: The present invention provides a lentiviral vector system having a higher titer, while sustaining an excellent retrograde transport ability, particularly, in the brain. The present invention also provides a kit for preparing a retrograde transport viral vector comprising: (1) a packaging plasmid containing the gag gene and the pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing an target gene (a transgene); and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising a fused extracellular domain consisting of the N-terminal region of an extracellular domain of rabies virus glycoprotein (RV-G) and the C-terminal region of an extracellular domain of vesicular stomatitis virus glycoprotein (VSV-G), a transmembrane domain of RV-G or VSV-G, and an intracellular domain of VSV-G, and the like.
Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
Type:
Application
Filed:
October 3, 2014
Publication date:
April 9, 2015
Inventors:
Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
Abstract: A process for producing a protein product for addition to raw meat wherein the source of the protein product is animal muscle or mechanically deboned meat. The animal muscle tissue is mixed with water and homogenized. Protein in the homogenate is solubilized. Solubilized homogenate is heated to a temperature required for pasteurization and/or sterilization according to known standards. The homogenate is then adjusted to a value at which the protein precipitates. The precipitate is free of bacteria and toxins and can be used as meat or added to raw meat for delivery to a consumer as uncooked meat.
Abstract: The present invention discloses a transcription activator-like effector-based strategy, termed “TALEColor”, for labeling specific repetitive DNA sequences in human chromosomes. TALEs were custom designed for human telomeric repeats and fused with any of numerous fluorescent proteins (FPs). TALE-telomere-FP fusion proteins were used to detect telomeric sequence in both living cells and fixed cells. Using human cells with different average telomere lengths, TALEColor signals correlated positively with telomere length. TALEs were also designed to detect centromeric sequences unique to specific chromosomes, enabling localization of these specific human chromosomes in live cells. These methods may have significant potential both for basic chromosome and genome research as well as in clinical applications.
Abstract: Methods are provided for engineering non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins are also provided.
Type:
Application
Filed:
October 6, 2014
Publication date:
April 9, 2015
Applicant:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Bertrand E. Garcia-Moreno, Aaron Robinson
Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.
Type:
Application
Filed:
October 8, 2014
Publication date:
April 9, 2015
Inventors:
Lawrence Chan, Hideto Kojima, Tomoya Terashima
Abstract: Compositions that include at least a portion of a flagellin and an antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to infection.
Type:
Application
Filed:
December 17, 2014
Publication date:
April 9, 2015
Inventors:
Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
Abstract: Disclosed herein are fluorescent proteins and Split-Fluorescent proteins (SFPs) including Split-Green Fluorescent Proteins, such as tripartite split-GFPs. Nucleic acid molecules encoding the fluorescent proteins and SFPs, as well as methods of using the fluorescent proteins and SFPs, are also disclosed. For example, methods of detecting protein-protein interactions are disclosed herein.
Abstract: The present invention is within the field of administration of biopharmaceuticals. More specifically, the invention provides for oral administration of a compound comprising a moiety which confers a desired therapeutic activity; and a polypeptide moiety which binds to albumin.
Abstract: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.
Type:
Application
Filed:
December 15, 2014
Publication date:
April 9, 2015
Inventors:
Judith DEL CAMPO ASCARATEIL, Fergal HILL
Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
Type:
Application
Filed:
October 3, 2014
Publication date:
April 9, 2015
Inventors:
Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
Abstract: The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.